Quarterly revenue of $130.8 million, up 30% from a year ago Quarterly EPS was $0.05, up 171% from a year agoTAIPEI, Taiwan, May 14, 2026 (GLOBE NEWSWIRE) — Asia Pacific Wire & Cable Corporation Limited (“APWC” or the “Company”) (NASDAQ: APWC) today announced its financial results for the first quarter ended March 31, 2026. Quarterly revenue was $130.8 million, down 2% from the previous quarter and up 30% from a year ago. For the quarter, earnings per share were $0.05, down 71% from the previous quarter and up 171% from a year ago. Copper unit volume, measured by the tonnage of copper contained in the wire and cable sold, decreased 2% sequentially and increased 5% from a year ago. This does not include other raw materials, such as aluminum and insulation materials. Q1 Fiscal 2026 SummaryQ1 Financial...

First Quarter Highlights – 2026 vs. 2025Verification and certification revenue increased to $4.4 million from $4.2 million Product sales increased slightly to $713,000 from $702,000 Total revenue increased to $5.4 million from $5.3 million Net income of $92,000, or $0.02 per share, up from $31,000, or $0.01 per share Company bought back 24,469 shares of its common stock at a cost of $293,000 Total buybacks since plan inception (including private purchases): 1,399,121 shares at a cost of approximately $15.5 millionCASTLE ROCK, Colo., May 14, 2026 (GLOBE NEWSWIRE) — Where Food Comes From, Inc. (WFCF) (Nasdaq: WFCF), the most trusted resource for independent, third-party verification of food production practices in North America, today announced financial results for its first quarter ended March 31, 2026. “We are pleased with...

First Quarter 2026 Net Loss of $1,546,000 ($0.46 loss per share) v. Net Loss of $2,152,000 ($0.65 loss per share) in Prior Year Comparable Period First Quarter 2026 EBITDA, as adjusted, was a loss of $1,313,000 ($0.39 loss per share) v. loss of $1,949,000 ($0.59 loss per share) in Prior Year Comparable Period Backlog at March 31, 2026 was $13.2 million compared to $12.3 million at December 31, 2025 HAUPPAUGE, N.Y., May 14, 2026 (GLOBE NEWSWIRE) — Orbit International Corp. (OTCID Basic Market:ORBT) today announced results for the first quarter ended March 31, 2026. First Quarter 2026 vs. First Quarter 2025Net sales were $5,245,000, as compared to $4,726,000. Gross margin was 23.3%, as compared to 12.4%. Net loss was $1,546,000 ($0.46 loss per share), as compared to a net loss of $2,152,000 ($0.65 loss per share). Earnings before...

 Secured strategic financing vehicle for up to $40 million Positive FDA feedback supports single-arm pivotal trial for potential registration of SENTI-202 in initial indication of Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) Continued operational streamlining contributed to substantially reduced quarterly net loss and cash burn SOUTH SAN FRANCISCO, Calif., May 14, 2026 (GLOBE NEWSWIRE) — Senti Biosciences Holdings, Inc. (Nasdaq: SNTI) (Senti Bio), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today reported financial results for the first quarter ended March 31, 2026, and provided recent business highlights. “We entered 2026 with a clear focus on advancing SENTI-202 and extending our operational runway while positioning the company...

LAS VEGAS, May 14, 2026 (GLOBE NEWSWIRE) — Live Ventures Incorporated (Nasdaq: LIVE) (“Live Ventures” or the “Company”), a diversified holding company, today announced financial results for its fiscal second quarter ended March 31, 2026.  Fiscal Second Quarter 2026 Key Highlights:Revenue was $102.9 million, compared to $107.0 million in the prior-year period Gross margin increased 80 basis points to 33.6%, compared to 32.8% in the prior-year period Operating loss was $2.0 million, compared to operating income of $2.1 million in the prior-year period.Excluding a non-cash goodwill impairment charge of approximately $4.0 million in the Steel Manufacturing segment, the fiscal second quarter 2026 operating income would have been approximately $2.0 millionNet loss was $2.4 million and diluted loss per share was $0.80, compared...

– Halneuron® Phase 2b trial in Chemotherapy Induced Neuropathy on track for top-line results in fall 2026 – – FDA acceptance of SP16 Investigational New Drug Application for the treatment of Chemotherapy Induced Pain and Neuropathy – – Announces Worldwide Development and Commercialization Partnership for Legacy Antiviral Assets with potential value up to $100M to Dogwood and its current and former shareholders – ALPHARETTA, Ga., May 14, 2026 (GLOBE NEWSWIRE) — Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (“Dogwood” or the “Company”), a company that focuses on developing first-in-class, new non-opioid medicines to treat pain and neuropathy, today announced financial results for the first quarter ended March 31, 2026. “Dogwood is off to a strong operational start to 2026 driven by significant pipeline progress...

Delivers 900 Basis Point Gross Margin Expansion, Net Loss Cut 51% and $21 to $22 Million Annual Revenue Visibility Turnaround Momentum MCLEAN, Va., May 14, 2026 (GLOBE NEWSWIRE) — Cycurion, Inc. (NASDAQ: CYCU) (“Cycurion” or the “Company”), a leader in AI-driven cybersecurity and national security solutions with trusted relationships across the U.S. Government, numerous leading corporations, and high-profile individuals across all industries, announced today results for the first quarter ended March 31, 2026. “The first quarter of 2026 marks a clear inflection point in our transformation,” said Kevin Kelly, Chairman and Chief Executive Officer of Cycurion. “We nearly doubled gross margins, significantly reduced operating expenses and executed binding agreements to acquire Halo Privacy and...

—New Clinical and Translational Data Presented at Major Medical Meetings Further Confirms the Disease-Modifying Potential of Nebokitug in Primary Sclerosing Cholangitis and Suggests Possible Additional Benefit in PSC Patients with Co-Existing IBD— —Company Continues to Advance Multiple Partnering Options for Nebokitug— TEL AVIV, Israel, May 14, 2026 (GLOBE NEWSWIRE) — Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical-stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced financial and operating results for the first quarter ended March 31, 2026, and provided a corporate update. “In the first quarter we continued to have productive discussions with potential strategic partners while releasing new data analyses that further extend our understanding...

Prenetics records Q1 2026 revenue of $36.0 million with IM8 revenue of $33.8 million, up 23.1% from IM8 revenue of $27.4 million in Q4 2025 Raises full-year 2026 IM8 revenue guidance to $190 million to $210 million (previously $180 million to $200 million) Company projects Q2 2026 revenue of $46 million to $48 million, with IM8 contributing $44 million to $46 million, representing approximately 33% sequential quarterly growth for IM8 IM8 announces the launch of 3 new SKUs in Q4 with Hydration, Creatine and Kids’ Gummies Prenetics divests full stake of digital assets for $41.3 million in proceeds, further boosting its cash balance Prenetics executed approximately $19 million of previously announced $40 million share buyback program Appointed consumer supplements finance veteran Brian J. Rosin as Chief Financial Officer of IM8 Company to...

N. WINDHAM, Maine, May 14, 2026 (GLOBE NEWSWIRE) — Synergy CHC Corp. (NASDAQ: SNYR) (“Synergy” or the “Company”), a consumer health and wellness company, is announcing its financial results for the three months ended March 31, 2026. “Our first quarter results reflect continued execution and the growing momentum of our functional beverage business,” said Jack Ross, CEO of Synergy CHC Corp. “During the quarter, we generated over $650,000 in functional beverage revenue, exceeding our total beverage revenue for all of 2025. This performance reflects the success of our expanding retail and distribution partnerships across the U.S., supported by healthy sell-through that is already driving increased reorder activity. Reflecting this momentum, our beverage division is operating at an estimated annual run rate exceeding $4 million. With...